Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Longboard Pharmaceuticals, Inc. LBPH NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
42/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$61.00
+1.7%

Longboard Pharmaceuticals, Inc. (LBPH) is a Biotechnology company in the Healthcare sector, currently trading at $59.98. It has a SharesGrow Score of 41/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is LBPH = $61 (+1.7% upside).

Net income is $54M (loss), growing at -58.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $475,000 against $41M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 5.14 (strong liquidity). Debt-to-assets is 0.9%. Total assets: $51M.

Analyst outlook: 5 / 9 analysts rate LBPH as buy (56%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 50/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 46/100 (Partial), Income ?/100 (Fail).

$61.00
▲ 1.7% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Longboard Pharmaceuticals, Inc., the average price target is $61.00, with a high forecast of $90.00, and a low forecast of $16.00.
Highest Price Target
$90.00
Average Price Target
$61.00
Lowest Price Target
$16.00

LBPH SharesGrow Score Overview

50/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 50/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 46/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — LBPH

~
VALUE Partial
50/100
LBPH trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $61, implying +1.7% from the current price $60. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
LBPH: +0%/yr revenue is, -58.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet LBPH: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 5.14 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
LBPH: Gross margin is 0% (+0 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
46/100
Analyst outlook: 5 / 9 analysts rate LBPH as buy (56%). Analyst consensus target is $61 (+1.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
Market Cap$2.34B
Beta (1Y)1.09
Share Statistics
EPS (TTM)-2.39
Shares Outstanding$22.73M
IPO Date2021-03-12
Employees50
CEOKevin R. Lind
Financial Highlights & Ratios
Gross Profit$-5K
EBITDA$-56.75M
Net Income$-54.42M
Operating Income$-56.76M
Total Cash$48.5M
Total Debt$475K
Net Debt$-13.86M
Total Assets$50.7M
Price / Earnings (P/E)-25.1
Analyst Forecast
1Y Price Target$60.00
Target High$90.00
Target Low$16.00
Upside+0.0%
Rating ConsensusBuy
Analysts Covering9
Buy 56% Hold 44% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS54300N1037

Price Chart

Track all markets on TradingView
LBPH
Longboard Pharmaceuticals, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology

People Also View

CELC
CELC
Celcuity Inc.
$120.85
+0.37%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 DSGN
DSGN
Design Therapeutics, Inc.
$12.64
+2.35%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message